Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | HPGD | P15428 | 1/20 | 0.57 |
| ▸ | MDH2 | P40926 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | LTA4H | P09960 | 5/20 | 0.55 |
| ▸ | PLA2G2A | P14555 | 5/20 | 0.55 |
| ▸ | MEN1 | O00255 | 3/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.55 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.55 |
| ▸ | TRPM8 | Q7Z2W7 | 3/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | HTR1D | P28221 | 3/20 | 0.53 |
| ▸ | POLB | P06746 | 2/20 | 0.53 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.51 |
| ▸ | KIF20A | O95235 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2084401 | 0.91 | MDH2 (0.66) | ALDH1A1HPGDMDH2SMN1; SMN2MEN1 | |
| SCHEMBL11620503 | 0.89 | TRPM8 (0.61) | ALDH1A1HPGDMDH2SMN1; SMN2LTA4H | |
| SCHEMBL9023222 | 0.88 | NR4A2 (0.66) | ALDH1A1HPGDMDH2SMN1; SMN2LTA4H | |
| SCHEMBL11602121 | 0.88 | ALDH1A1 (0.61) | ALDH1A1HPGDMDH2SMN1; SMN2LTA4H | |
| SCHEMBL11194622 | 0.86 | ALDH1A1 (0.59) | ALDH1A1HPGDMDH2SMN1; SMN2LTA4H | |
| SCHEMBL6764594 | 0.85 | MAOB (0.61) | ALDH1A1HPGDMDH2SMN1; SMN2LTA4H | |
| SCHEMBL7448403 | 0.85 | HTR1D (0.57) | ALDH1A1HPGDMDH2SMN1; SMN2LTA4H | |
| SCHEMBL5114492 | 0.85 | POLB (0.59) | ALDH1A1HPGDMDH2SMN1; SMN2LTA4H | |
| SCHEMBL14554210 | 0.84 | MEN1 (0.60) | ALDH1A1HPGDMDH2SMN1; SMN2LTA4H | |
| SCHEMBL28123392 | 0.83 | TRPM8 (0.60) | ALDH1A1HPGDMDH2SMN1; SMN2LTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7129250-B2 | Neuroprotective and anti-proliferative compounds | AEGERA THERAPEUTICS INC. (CA) | 2006-10-31 | — | — | US | disclosed |
| US-6867198-B2 | Agents and methods for the treatment of proliferative diseases | ELI LILLY AND COMPANY (US) | 2005-03-15 | — | — | US | disclosed |
| US-20040220202-A1 | Neuroprotective and anti-proliferative compounds | AEGERA THERAPEUTICS INC. (CA) | 2004-11-04 | — | — | US | disclosed |
| US-6743785-B2 | KINASE INHIBITORS; ANNULATED PYRROLE AND INDOLE RINGS; PYRROLO (3,2,1-HI)INDOLES; 3-(5,5-DIMETHYL-5,6-DIHYDRO-4H-PYRROLO (3,2,1-IJ)QUINOLIN-1-YL)-4-(1,2,3,4-TETRAHYDRO-(1,4) DIAZEPINO(6,7,1-HI)INDOL-7-YL)-PYRROLE-2,5-DIONE | ELI LILLY AND COMPANY | 2004-06-01 | — | — | US | disclosed |
| US-20040102467-A1 | Neuroprotective and anti-proliferative compounds | AEGERA THERAPEUTICS INC. (CA) | 2004-05-27 | — | — | US | disclosed |
| EP-1250334-B1 | Medicaments useful for the treatment of proliferative diseases | LILLY CO ELI (US) | 2004-05-19 | — | — | EP | disclosed |
| US-20030229026-A1 | Agents and methods for the treatment of proliferative diseases | ELI LILLY AND COMPANY | 2003-12-11 | — | — | US | disclosed |
| US-20030092676-A1 | Agents and method for the treatment of proliferative diseases | ELI LILLY AND COMPANY | 2003-05-15 | — | — | US | disclosed |
| EP-1283836-A2 | NEUROPROTECTIVE AND ANTI-PROLIFERATIVE COMPOUNDS | Aegera Therapeutics Inc. (CA) | 2003-02-19 | — | — | EP | disclosed |
| EP-1250334-A2 | AGENTS AND METHODS FOR THE TREATMENT OF PROLIFERATIVE DISEASES | ELI LILLY AND COMPANY (US) | 2002-10-23 | — | — | EP | disclosed |
| EP-1242420-A2 | AGENTS AND METHODS FOR THE TREATMENT OF PROLIFERATIVE DISEASES | ELI LILLY AND COMPANY (US) | 2002-09-25 | — | — | EP | disclosed |
| WO-2001087887-A2 | NEUROPROTECTIVE AND ANTI-PROLIFERATIVE COMPOUNDS | AEGERA THERAPEUTICS INC. (CA) | 2001-11-22 | — | — | WO | disclosed |
| WO-2001044235-A2 | AGENTS AND METHODS FOR THE TREATMENT OF PROLIFERATIVE DISEASES | ELI LILLY AND COMPANY (US) | 2001-06-21 | — | — | WO | disclosed |
| WO-2001044247-A2 | AGENTS AND METHODS FOR THE TREATMENT OF PROLIFERATIVE DISEASES | ELI LILLY AND COMPANY (US) | 2001-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030092676-A1 | Agents and method for the treatment of proliferative diseases | MKI67, CDKN1A, CDK4 | ALDH1A1 1225/4885HPGD 1210/4885MDH2 1344/4885 |
| US-20040220202-A1 | Neuroprotective and anti-proliferative compounds | NLN, MKI67, BDNF | ALDH1A1 892/4885HPGD 475/4885MDH2 494/4885 |
| US-20040102467-A1 | Neuroprotective and anti-proliferative compounds | MKI67, NLN, BDNF | ALDH1A1 746/4885HPGD 405/4885MDH2 453/4885 |
| US-20030229026-A1 | Agents and methods for the treatment of proliferative diseases | MKI67, CDKN1A, CDK1 | ALDH1A1 1132/4885HPGD 1187/4885MDH2 1438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.